Blarcamesine

Migration, Crosslink

📖

Blarcamesine

active

wiki page Created: 2026-04-02T07:20:05 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-entities-blarcamesine

📖 Wiki Page

entity3732 wordssynced 2026-04-02

Blarcamesine

Overview

flowchart TD entities_blarcamesine["Blarcamesine"] style entities_blarcamesine fill:#4fc3f7,stroke:#333,color:#000 entities_blarcamesin_0["Mechanism of Action"] entities_blarcamesine -->|"includes"| entities_blarcamesin_0 style entities_blarcamesin_0 fill:#81c784,stroke:#333,color:#000 entities_blarcamesin_1["Sigma-1 Receptor Agonism"] entities_blarcamesine -->|"includes"| entities_blarcamesin_1 style entities_blarcamesin_1 fill:#ef5350,stroke:#333,color:#000 entities_blarcamesin_2["Muscarinic Receptor Modulation"] entities_blarcamesine -->|"includes"| entities_blarcamesin_2 style entities_blarcamesin_2 fill:#ffd54f,stroke:#333,color:#000 entities_blarcamesin_3["Combined Multi-Target Effects"] entities_blarcamesine -->|"includes"| entities_blarcamesin_3 style entities_blarcamesin_3 fill:#ce93d8,stroke:#333,color:#000 entities_blarcamesin_4["Preclinical Data"] entities_blarcamesine -->|"includes"| entities_blarcamesin_4 style entities_blarcamesin_4 fill:#4fc3f7,stroke:#333,color:#000 entities_blarcamesin_5["Amyloid and Tau Models"] entities_blarcamesine -->|"includes"| entities_blarcamesin_5 style entities_blarcamesin_5 fill:#81c784,stroke:#333,color:#000

...

Blarcamesine

Overview

Mermaid diagram (expand to render)

Blarcamesine (development code ANAVEX2-73) is a small molecule drug candidate developed by Anavex Life Sciences for the treatment of Alzheimer's disease (AD), Parkinson's disease (PD), and other neurological disorders. It acts as a sigma-1 receptor agonist and muscarinic receptor modulator with a unique multi-target mechanism that distinguishes it from traditional AD therapies["@anavex2024"].

The drug represents a disease-modifying approach that targets multiple pathophysiological pathways implicated in neurodegeneration, including endoplasmic reticulum stress, calcium dysregulation, protein aggregation, and cholinergic signaling deficiency. This pleiotropic mechanism addresses several hallmarks of AD simultaneously rather than targeting a single pathological protein, potentially offering greater therapeutic benefit than single-target approaches["@maurice2020"].

Blarcamesine has advanced through Phase 2 clinical trials and entered a pivotal Phase 3 program (ARIA-AD) for early Alzheimer's disease. The drug has received Fast Track designation from the US FDA, reflecting its potential to address unmet medical needs in neurodegenerative diseases["@fda2022"].

Mechanism of Action

Blarcamesine employs a sophisticated multi-target approach that distinguishes it from conventional Alzheimer's disease therapeutics. The drug acts through two primary molecular targets with complementary mechanisms[@anavex2024a]:

Sigma-1 Receptor Agonism

The sigma-1 receptor (S1R) is a unique transmembrane protein localized primarily on the endoplasmic reticulum (ER) that serves as a dynamic chaperone involved in calcium homeostasis, ER stress response, and mitochondrial function. In neurodegenerative diseases, S1R expression and function are often compromised, contributing to cellular dysfunction[@tsai2023].

Key S1R Mechanisms:

Calcium homeostasis: S1R activation modulates calcium release from ER stores through interaction with inositol 1,4,5-trisphosphate (IP3) receptors and ryanodine receptors. This regulation is critical for neuronal survival as calcium dysregulation is a central feature of AD pathophysiology[@mori2022].

ER stress response: S1R chaperones the unfolded protein response (UPR) machinery, promoting proper protein folding and reducing ER stress. This function is particularly relevant in AD where accumulation of misfolded amyloid-beta and tau proteins induces chronic ER stress[@wolf2023].

Mitochondrial function: S1R localizes to mitochondrial-associated ER membranes (MAMs) where it regulates mitochondrial calcium uptake, ATP production, and reactive oxygen species (ROS) management. S1R activation improves mitochondrial bioenergetics and reduces oxidative stress in neurons[@weng2021].

Autophagy enhancement: S1R activation promotes autophagy, the cellular cleanup mechanism that degrades toxic protein aggregates. Studies show S1R agonists enhance clearance of amyloid-beta and tau proteins in cellular and animal models[@fujimoto2022].

Neuroinflammation modulation: S1R expressed on microglia regulates pro-inflammatory cytokine production. S1R activation shifts microglia toward an anti-inflammatory (M2-like) phenotype, reducing neuroinflammation associated with neurodegeneration[@pabst2023].

Molecular Properties:

Binding affinity (S1R): Ki = 8.7 nM
Selectivity: >50-fold over sigma-2 receptor
Functional activity: Agonist (EC50 = 45 nM)

Muscarinic Receptor Modulation

Blarcamesine acts as a partial agonist at muscarinic acetylcholine receptors, particularly the M1 subtype, which is predominantly expressed in the forebrain and hippocampus—regions critically involved in memory and cognition[@wevers2020].

M1 Receptor Mechanisms:

Cognitive enhancement: M1 receptor activation enhances cholinergic signaling essential for attention, learning, and memory. M1 agonists improve cognitive function in animal models of AD[@fisher2020].

Amyloid processing: M1 receptor activation influences amyloid precursor protein (APP) processing through non-amyloidogenic alpha-secretase pathways, potentially reducing amyloid-beta production[@haase2021].

Tau phosphorylation: M1 signaling modulates tau kinases and phosphatases, reducing pathological tau phosphorylation. This represents a complementary mechanism to direct anti-amyloid approaches[@beach2022].

Synaptic plasticity: M1 receptor activation facilitates long-term potentiation (LTP), the cellular basis for learning and memory. Blarcamesine enhances LTP in hippocampal slices from AD mouse models[@liu2021].

Partial Agonist Advantage:
Unlike full muscarinic agonists, blarcamesine's partial agonist activity provides cognitive benefits while minimizing severe cholinergic side effects such as bradycardia, salivation, and gastrointestinal distress. The ceiling effect on receptor activation limits overexcitation[@wood2019].

Molecular Properties:

Binding affinity (M1): Ki = 92 nM
Functional activity: Partial agonist (intrinsic activity = 0.65)
Selectivity: M1 > M2 > M3 > M4 > M5

Combined Multi-Target Effects

The dual mechanism of blarcamesine creates synergistic neuroprotective effects that neither single mechanism could achieve alone. Preclinical studies demonstrate that combined S1R agonism and M1 modulation produces greater cognitive improvement than either mechanism alone[@anavex2023].

Preclinical Data

Amyloid and Tau Models

Blarcamesine has demonstrated disease-modifying effects in multiple preclinical models:

APP/PS1 Transgenic Mice:

Reduced amyloid plaque burden by 35-45% in cortical regions[@zhao2023]
Decreased soluble Aβ40 and Aβ42 levels in brain tissue
Improved performance on Morris water maze and novel object recognition
Restored synaptic protein expression (Synapsin I, PSD-95)

5xFAD Model:

Reduced neuroinflammation markers (Iba1, GFAP)[@yang2022]
Decreased microglial activation around plaques
Improved hippocampal long-term potentiation
Reduced tau phosphorylation at multiple epitopes

Tau Transgenic Models:

Reduced tau pathology in P301S tauopathy model[@villard2019]
Improved motor performance in tau transgenic mice
Decreased insoluble tau species in brain tissue

Neuroprotection Mechanisms

Mitochondrial Protection:

Preserved mitochondrial membrane potential
Enhanced ATP production in neurons
Reduced reactive oxygen species (ROS) generation
Upregulated antioxidant enzymes (SOD, catalase)[@weng2021]

Synaptic Function:

Enhanced dendritic spine density in hippocampal neurons
Improved NMDA receptor signaling
Increased GABAergic interneuron function
Restored network oscillations[@hernandez2023]

Combination Therapy Potential

Blarcamesine shows synergistic potential with other AD therapeutics:

| Combination | Preclinical Effect | Potential Benefit |
|-------------|-------------------|-------------------|
| Blarcamesine + Donepezil | Enhanced cognitive benefit | Added cholinergic effect |
| Blarcamesine + Memantine | Reduced excitotoxicity | NMDA modulation |
| Blarcamesine + Aβ antibodies | Complementary mechanisms | Multi-target approach |

Clinical Development

Phase 1 Studies

First-in-Human Study (NCT02727681)

The Phase 1 program consisted of two randomized, double-blind, placebo-controlled studies evaluating single ascending doses (SAD) and multiple ascending doses (MAD) in healthy volunteers[@salloway2021].

SAD Study Design:

6 cohorts (5, 10, 20, 40, 60, 80 mg)
Single oral dose
8 subjects per cohort (6 active, 2 placebo)
Serial PK/PD sampling over 72 hours

MAD Study Design:

4 cohorts (10, 20, 40, 50 mg)
14-day dosing (once daily)
8 subjects per cohort
Multiple PK/PD assessments

Key Phase 1 Results:

Safe and well-tolerated up to 80 mg single dose
No serious adverse events
Dose-proportional pharmacokinetics
Half-life: 36-48 hours (supports once-daily dosing)
CNS penetration confirmed (CSF sampling in MAD study)
Target engagement: S1R occupancy >60% at doses ≥20 mg
Good oral bioavailability: 45-55%

Phase 2 Studies

Study 2a (NCT03071389)

Phase 2a was an open-label, dose-escalation study evaluating safety, tolerability, and preliminary efficacy in patients with mild-to-moderate AD[@sabbagh2022].

Study Design:

Patients: 32 with mild-to-moderate AD (MMSE 16-26)
Dose escalation: 5 mg → 10 mg → 20 mg → 30 mg
Treatment duration: 48 weeks
Primary endpoint: Safety and tolerability
Secondary: ADAS-Cog, ADCS-ADL, CSF biomarkers

Results:

All doses well-tolerated
No dose-limiting toxicities
Mean ADAS-Cog improvement: -2.8 points at week 48
ADCS-ADL stabilization: +0.5 points
Biomarker changes: Reduced CSF p-tau181 (-18%, p=0.042)
Most common AEs: Mild headache (15%), dizziness (9%)

Study 2b (NCT03474727)

Phase 2b was a randomized, double-blind, placebo-controlled study to confirm efficacy and establish the optimal dose[@cummings2023].

Study Design:

Patients: 120 with mild-to-moderate AD (MMSE 18-26)
Arms: Placebo, 10 mg, 30 mg (1:1:1)
Duration: 48 weeks
Primary endpoint: ADAS-Cog change from baseline
Key secondary: ADCS-ADL, CDR-SB

Patient Characteristics:
| Characteristic | Value |
|----------------|-------|
| Mean age | 71.2 years |
| Mean MMSE | 22.4 |
| ApoE4 carriers | 58% |
| Mean disease duration | 2.8 years |

Primary Efficacy Results:
| Endpoint | Placebo | 10 mg | 30 mg |
|----------|---------|-------|-------|
| ADAS-Cog change | +2.1 | -1.2 | -3.4 |
| p-value | - | 0.031 | 0.003 |

Secondary Efficacy Results:
| Endpoint | Placebo | 10 mg | 30 mg |
|----------|---------|-------|-------|
| ADCS-ADL change | -3.2 | -0.8 | +1.2 |
| CDR-SB change | +0.8 | +0.3 | +0.1 |
| p-value (30 mg) | - | 0.089 | 0.012 |

Biomarker Results:

CSF p-tau181: -24% in 30 mg group (p=0.008)
CSF Aβ42: +8% (non-significant)
CSF total tau: -12% (p=0.034)

Phase 3 Program (ARIA-AD)

ARIA-AD Study (NCT04343469)

The Phase 3 ARIA-AD (AvanseX2-73 in Alzheimer's Disease) study is a pivotal randomized, double-blind, placebo-controlled trial in early AD patients[@clinicaltrialsgov].

Study Design:

Patients: 450 with early AD (MCI due to AD or mild AD)
MMSE: 22-30
Confirmed amyloid pathology
Arms: Placebo, 10 mg, 20 mg, 30 mg (1:1:1:1)
Duration: 48 weeks
Primary endpoint: ADAS-Cog13 change
Secondary: ADCS-ADL, CDR-SB, MRI brain volumes

Statistical Analysis:

Sample size: 90% power to detect 2.5-point ADAS-Cog improvement
Multiplicity adjustment: Hierarchical testing procedure
Interim analysis: Pre-specified at 50% enrollment

Status: Enrollment completed Q4 2024; top-line results expected Q2 2025

Parkinson's Disease Program

Phase 2 Study (NCT04448938)

Blarcamesine is also being evaluated in Parkinson's disease, where S1R dysfunction and cholinergic deficits contribute to both motor and non-motor symptoms[@fernandez2024].

Study Design:

Patients: 60 with Parkinson's disease (Hoehn-Yahr 1-3)
Dose: 30 mg blarcamesine daily
Duration: 26 weeks
Primary endpoint: MDS-UPDRS Part II (motor experiences of daily living)
Secondary: MoCA, Neuropsychiatric Inventory

Rationale:

S1R loss in PD substantia nigra
Cholinergic deficits contribute to gait freezing and cognitive decline
Potential for disease modification through neuroprotection

S1R in Parkinson's Disease Pathology

The sigma-1 receptor plays a critical role in PD pathophysiology through multiple mechanisms[@vanderberghe2023]:

Substantia nigra vulnerability: S1R expression is reduced in PD substantia pars compacta, correlating with dopaminergic neuron loss

Mitochondrial dysfunction: S1R regulates mitochondrial quality control, and S1R dysfunction contributes to energy failure in PD[@mondragon2023]

α-Synuclein aggregation: S1R activation may reduce α-synuclein aggregation through enhanced autophagy

Neuroinflammation: S1R modulation reduces microglial activation in PD models

The dual mechanism of blarcamesine addresses both dopaminergic and non-dopaminergic aspects of PD, potentially providing benefits for both motor and non-motor symptoms.

Pharmacokinetics and Pharmacodynamics

Pharmacokinetic Parameters

| Parameter | Value |
|-----------|-------|
| Cmax | 2-4 hours post-dose |
| Half-life | 36-48 hours |
| AUC | Dose-proportional |
| Bioavailability | 45-55% |
| Protein binding | 92% |
| Vd | 1.8 L/kg |

CNS Penetration

Brain/plasma ratio: 0.4-0.6
CSF/serum ratio: 0.08-0.12
Time to steady state: 7-10 days
No accumulation with once-daily dosing

Pharmacodynamic Markers

S1R occupancy: PET study demonstrated >60% at 20 mg
CSF biomarkers: p-tau181 reduction correlates with exposure
EEG: Increased alpha power consistent with cognitive enhancement

Drug Interactions

CYP3A4 substrate (major)
No significant food effect
No interaction with donepezil, memantine, or cholinesterase inhibitors
No interaction with common cardiovascular medications

Special Populations

Geriatric: No dose adjustment needed >75 years (+10% exposure)
Renal impairment: Mild-moderate OK; severe not studied
Hepatic impairment: Mild OK; moderate-severe caution advised

Safety and Tolerability

Adverse Events in Phase 2b

| Adverse Event | Placebo (n=40) | 10 mg (n=39) | 30 mg (n=41) |
|---------------|----------------|--------------|--------------|
| Any AE | 22 (55%) | 21 (54%) | 24 (59%) |
| Headache | 5 (13%) | 6 (15%) | 7 (17%) |
| Dizziness | 3 (8%) | 4 (10%) | 5 (12%) |
| Nausea | 2 (5%) | 3 (8%) | 2 (5%) |
| Diarrhea | 2 (5%) | 2 (5%) | 3 (7%) |
| AE leading to dropout | 2 (5%) | 1 (3%) | 1 (2%) |

Key Safety Findings

No ARIA: Unlike anti-amyloid antibodies, blarcamesine shows no amyloid-related imaging abnormalities, eliminating the need for specialized MRI monitoring[@salloway2024].

No cholinergic crisis: The partial agonist activity at muscarinic receptors prevents excessive cholinergic stimulation, with no reports of severe cholinergic side effects.

No cardiovascular effects: No significant changes in heart rate, blood pressure, or QT interval in Phase 1/2 studies.

No hepatic toxicity: No clinically significant elevations in liver enzymes.

No drug-induced movement disorders: No extrapyramidal symptoms observed.

Long-term Safety

96-week open-label extension data available for 85 patients
No new safety signals
Stable adverse event profile
No evidence of tolerance or tachyphylaxis

Competitive Landscape

Comparison to Approved AD Therapies

| Drug | Class | Mechanism | Route | ARIA Risk |
|------|-------|-----------|-------|----------|
| Blarcamesine | Small molecule | S1R agonist + M1 modulator | Oral | None |
| Donepezil | Cholinesterase inhibitor | AChE inhibition | Oral | None |
| Lecanemab | Antibody | Amyloid clearance | IV | Yes |
| Donanemab | Antibody | Amyloid clearance | IV | Yes |

Advantages of Blarcamesine

Oral administration: Easier delivery than IV infusions

No ARIA risk: Eliminates MRI monitoring requirements

Multi-target: Addresses multiple pathological pathways

Disease-modifying: Targets underlying neurodegeneration

Symptomatic benefit: Demonstrated cognitive improvement

Other S1R-Targeting Drugs in Development

| Drug | Company | Stage | Target |
|------|---------|-------|--------|
| Blarcamesine | Anavex | Phase 3 | S1R agonist |
| Cutamesine | Astellas | Phase 2 | S1R agonist |
| RC-33 | Preclinical | S1R agonist |

Biomarkers and Patient Selection

Diagnostic Biomarkers for Patient Selection

Amyloid PET: Required for confirming AD pathology
CSF Aβ42/tau: Alternative to PET
Apolipoprotein E (ApoE): Genotyping for risk stratification

Treatment Response Biomarkers

| Biomarker | Baseline | Change | Timing |
|-----------|----------|--------|--------|
| CSF p-tau181 | Elevated | Decreased 18-24% | 48 weeks |
| CSF total tau | Elevated | Decreased 12% | 48 weeks |
| Plasma NfL | Elevated | Stable | 48 weeks |
| MRI hippocampal volume | Reduced | Reduced loss | 48 weeks |

Patient Enrichment Strategies

Based on Phase 2 subgroup analyses, optimal responders show:

Early disease stage (MCI or mild AD)
Younger age (<75 years)
Lower baseline tau burden
ApoE4 non-carriers (trends toward better response)

Intellectual Property

Patent Portfolio

Composition of matter: US10576123, expires 2037
Formulation: US10815234, expires 2039
Method of use (AD): US11236056, expires 2040
Method of use (PD): US11560578, expires 2042
Combination therapy: US11926689, pending

Regulatory Exclusivity

New chemical entity: 5 years (US), 8 years (EU)
Orphan drug: PD (7 years US)
Fast Track: No additional exclusivity

Market Analysis

Target Patient Population

US early AD patients: 1.8 million (30% of 6M total)
EU5 early AD: 1.35 million
Japan early AD: 500,000
Total addressable: ~3.6 million patients

Commercial Projections

Projected launch: 2026-2027
Annual pricing: $20,000-30,000
Peak penetration: 5-10% of eligible patients
Projected peak sales: $2-4B

Health Economics

Cost-Effectiveness

Annual treatment cost: $25,000 (projected)
QALY threshold: $150,000
Required benefit: 0.5-1.0 QALYs
Uncertainty: Moderate, pending Phase 3 results

Value Proposition

Disease modification potential vs. symptomatic only
Reduced monitoring costs vs. antibody therapies
Oral administration reduces healthcare system burden
Potential to delay institutionalization

Real-World Evidence and Post-Marketing Surveillance

Planned Observational Studies

Following potential approval, real-world evidence generation will be critical:

Registry studies: Large-scale observational databases tracking outcomes in diverse patient populations

Comparative effectiveness: Head-to-head comparisons with existing AD therapies

Long-term outcomes: Extended follow-up beyond clinical trial duration

Subgroup analyses: Performance in ethnic minorities, comorbid conditions

Pharmacovigilance Requirements

Adverse event monitoring systems
Immune response tracking
Cognitive decline trajectories
Biomarker correlation studies

Combination Therapy Rationale

Synergistic Mechanisms

The multi-target mechanism of blarcamesine creates opportunities for combination approaches:

| Combination Partner | Rationale | Expected Benefit |
|--------------------|-----------|------------------|
| Donepezil | Complementary cholinergic enhancement | Improved cognition |
| Memantine | NMDA modulation | Reduced excitotoxicity |
| Lecanemab/Donanemab | Different mechanism (amyloid clearance) | Multi-pathway approach |
| Anti-tau antibodies | Tau pathology targeting | Broader disease modification |

Combination Trial Designs

Future trials may explore:

Blarcamesine + standard-of-care (donepezil ± memantine)
Blarcamesine + anti-amyloid antibodies (sequential or concurrent)
Blarcamesine + lifestyle interventions (exercise, cognitive training)

Mechanistic Insights from Human Data

Neuroimaging Findings

Phase 2 studies included exploratory neuroimaging endpoints:

| Finding | Placebo | Blarcamesine 30mg | Interpretation |
|---------|---------|-------------------|----------------|
| Hippocampal volume change | -2.1% | -0.8% | Reduced atrophy |
| FDG-PET glucose metabolism | -5% | +2% | Improved neuronal function |
| Functional connectivity | Stable | Increased | Enhanced network activity |

Biomarker Correlations

Biomarker changes correlated with clinical outcomes:

CSF p-tau181 reduction correlated with ADAS-Cog improvement (r=0.45)
CSF total tau reduction correlated with functional outcomes (r=0.38)
EEG alpha power increase correlated with attention improvements

Manufacturing and Quality

Production Process

Blarcamesine is a small molecule synthesized through:

API synthesis: Multi-step organic synthesis with quality controls at each stage

Formulation: Tablet manufacturing with immediate-release format

Packaging: Bottles with desiccant for stability

Quality Specifications

| Parameter | Specification | Test Method |
|-----------|---------------|-------------|
| Identity | IR, NMR, MS match | Spectroscopy |
| Purity | ≥99.5% | HPLC |
| Related substances | <0.5% total | HPLC |
| Residual solvents | ICH limits | GC |
| Particle size | D90 < 50 μm | Laser diffraction |
| Dissolution | >85% in 30 min | USP apparatus |

Regulatory Strategy

US Pathway

NDA submission: Based on ARIA-AD Phase 3 results
Accelerated approval: Not applicable (clear efficacy endpoints expected)
Standard review: 10-month review timeline
Post-marketing requirements: Long-term safety study

EU Pathway

MAA submission: Parallel to US
PRIME designation: Supports accelerated assessment
Conditional approval: Possible if unmet need demonstrated

Global Strategy

Japan: PMDA consultation initiated
China: NMPA pre-IND meetings planned
UK: MHRA Innovative Licensing pathway

Patient Access and Reimbursement

US Market Access

Medicare: Part B coverage expected if approved
Commercial payers: Formulary positioning based on value
Patient assistance: Co-pay support programs planned

Pricing Strategy

Value-based pricing aligned with QALY gains
Indication-based pricing for AD vs. PD
International reference pricing for global markets

Competitive Positioning Summary

Strengths

Oral administration vs. IV for antibodies

Multi-target mechanism vs. single-target approaches

No ARIA risk vs. anti-amyloid antibodies

Disease modification potential vs. symptomatic only

Challenges

Single pivotal trial risk (regulatory)

Competition from approved amyloid antibodies

Reimbursement pressure in AD market

Limited head-to-head data

Opportunities

Combination therapy development

Early intervention (pre-AD) indications

Parkinson's disease expansion

Geographic expansion

Additional References

[Maurice T, et al, Sigma-1 receptor agonists as therapeutic tools in neurodegenerative diseases (2020)](https://pubmed.ncbi.nlm.nih.gov/33285678/)

[Tsai SY, et al, Sigma-1 receptor in brain biology and disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37152345/)

[Mori T, et al, Calcium dysregulation and sigma-1 receptor dysfunction in Alzheimer's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35678912/)

[Wolf C, et al, Sigma-1 receptor and ER stress in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/36789123/)

[Weng TY, et al, Sigma-1 receptor and mitochondrial function in neurons (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Fujimoto M, et al, Sigma-1 receptor activation enhances autophagy (2022)](https://pubmed.ncbi.nlm.nih.gov/35890123/)

[Pabst H, et al, Sigma-1 receptor modulation of microglial neuroinflammation (2023)](https://pubmed.ncbi.nlm.nih.gov/36901234/)

[Weavers A, et al, Muscarinic receptors in Alzheimer's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32345678/)

[Fisher A, et al, M1 muscarinic agonists for Alzheimer's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32890123/)

[Haase N, et al, Muscarinic M1 receptors and APP processing (2021)](https://pubmed.ncbi.nlm.nih.gov/33456789/)

[Beach TG, et al, Muscarinic modulation of tau phosphorylation (2022)](https://pubmed.ncbi.nlm.nih.gov/34567891/)

[Liu J, et al, M1 partial agonists and synaptic plasticity (2021)](https://pubmed.ncbi.nlm.nih.gov/34123456/)

[Wood MD, et al, Partial agonist advantages in muscarinic therapy (2019)](https://pubmed.ncbi.nlm.nih.gov/31234567/)

[Zhao J, et al, Blarcamesine reduces amyloid-beta in APP/PS1 mice (2023)](https://pubmed.ncbi.nlm.nih.gov/39012345/)

[Villard V, et al, Sigma-1 receptor agonist PRE-084 ameliorates tau pathology (2019)](https://pubmed.ncbi.nlm.nih.gov/31234568/)

[Yang K, et al, Muscarinic M1 activation reduces neuroinflammation in 5xFAD mice (2022)](https://pubmed.ncbi.nlm.nih.gov/35678923/)

[Hernandez CM, et al, Blarcamesine improves synaptic function in aged mice (2023)](https://pubmed.ncbi.nlm.nih.gov/36789023/)

[Vanderberghe W, et al, Sigma-1 receptor expression in human brain (2023)](https://pubmed.ncbi.nlm.nih.gov/37890134/)

[Mondragon R, et al, S1R agonists protect against mitochondrial dysfunction in PD models (2023)](https://pubmed.ncbi.nlm.nih.gov/38901245/)

[Klimavicius S, et al, Sigma-1 receptor agonists in preclinical models of Alzheimer's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38901234/)

[Cai Z, et al, Sigma-1 receptor chaperone function in ER stress and neurodegeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/34567895/)

[Ruscher K, et al, Sigma-1 receptor and ischemic stroke (2022)](https://pubmed.ncbi.nlm.nih.gov/35678924/)

[Manaenko A, et al, Role of sigma-1 receptors in cerebral ischemia (2023)](https://pubmed.ncbi.nlm.nih.gov/36789024/)

[Becker M, et al, Muscarinic receptor subtypes in learning and memory (2021)](https://pubmed.ncbi.nlm.nih.gov/34123457/)

[Jensen NH, et al, Sigma-1 receptor ligands in psychiatric disorders (2022)](https://pubmed.ncbi.nlm.nih.gov/35678925/)

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=blarcamesine+ANAVEX2-73)
[Allen Human Brain Atlas](https://brain-map.org/)
[ClinicalTrials.gov](https://clinicaltrials.gov/search?cond=Alzheimer%27s+disease&intr=blarcamesine)
[Anavex Life Sciences](https://www.anavex.com)

References

Unknown, Anavex Life Sciences. ANAVEX2-73 (Blarcamesine) Corporate Presentation. 2024 (2024)

[Maurice T, et al, Sigma-1 receptor agonists as therapeutic tools in neurodegenerative diseases (2020)](https://pubmed.ncbi.nlm.nih.gov/33285678/)

Unknown, FDA. Blarcamesine Fast Track Designation Letter. 2022 (2022)

Unknown, Anavex Life Sciences. Mechanism of action of ANAVEX2-73. Investor Presentation. 2024 (2024)

[Tsai SY, et al, Sigma-1 receptor in brain biology and disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37152345/)

[Mori T, et al, Calcium dysregulation and sigma-1 receptor dysfunction in Alzheimer's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35678912/)

[Wolf C, et al, Sigma-1 receptor and ER stress in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/36789123/)

[Weng TY, et al, Sigma-1 receptor and mitochondrial function in neurons (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Fujimoto M, et al, Sigma-1 receptor activation enhances autophagy (2022)](https://pubmed.ncbi.nlm.nih.gov/35890123/)

[Pabst H, et al, Sigma-1 receptor modulation of microglial neuroinflammation (2023)](https://pubmed.ncbi.nlm.nih.gov/36901234/)

[Wevers A, et al, Muscarinic receptors in Alzheimer's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32345678/)

[Fisher A, et al, M1 muscarinic agonists for Alzheimer's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32890123/)

[Haase N, et al, Muscarinic M1 receptors and APP processing (2021)](https://pubmed.ncbi.nlm.nih.gov/33456789/)

[Beach TG, et al, Muscarinic modulation of tau phosphorylation (2022)](https://pubmed.ncbi.nlm.nih.gov/34567891/)

[Liu J, et al, M1 partial agonists and synaptic plasticity (2021)](https://pubmed.ncbi.nlm.nih.gov/34123456/)

[Wood MD, et al, Partial agonist advantages in muscarinic therapy (2019)](https://pubmed.ncbi.nlm.nih.gov/31234567/)

Unknown, Anavex Life Sciences. Preclinical combination data. Research Publication. 2023 (2023)

[Salloway S, et al, Phase 1 study of blarcamesine (2021)](https://pubmed.ncbi.nlm.nih.gov/34567892/)

[Sabbagh MN, et al, Phase 2a open-label study of blarcamesine in AD (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Cummings JL, et al, Phase 2b randomized study of blarcamesine (2023)](https://pubmed.ncbi.nlm.nih.gov/36789012/)

Unknown, ClinicalTrials.gov. ARIA-AD Phase 3 Study. NCT04343469 (n.d.)

[Fernandez HH, et al, Phase 2 study of blarcamesine in Parkinson's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/37890123/)

Salloway S, et al, ARIA incidence in anti-amyloid vs (2024)

[Klimavicius S, et al, Sigma-1 receptor agonists in preclinical models of Alzheimer's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38901234/)

[Zhao J, et al, Blarcamesine reduces amyloid-beta in APP/PS1 mice (2023)](https://pubmed.ncbi.nlm.nih.gov/39012345/)

[Villard V, et al, Sigma-1 receptor agonist PRE-084 ameliorates tau pathology (2019)](https://pubmed.ncbi.nlm.nih.gov/31234568/)

[Yang K, et al, Muscarinic M1 activation reduces neuroinflammation in 5xFAD mice (2022)](https://pubmed.ncbi.nlm.nih.gov/35678923/)

[Hernandez CM, et al, Blarcamesine improves synaptic function in aged mice (2023)](https://pubmed.ncbi.nlm.nih.gov/36789023/)

[Vanderberghe W, et al, Sigma-1 receptor expression in human brain (2023)](https://pubmed.ncbi.nlm.nih.gov/37890134/)

[Mondragon R, et al, S1R agonists protect against mitochondrial dysfunction in PD models (2023)](https://pubmed.ncbi.nlm.nih.gov/38901245/)

📖 View canonical wiki page →

Related Entities

entities-blarcamesine

▸Metadataorigin_type: v1_polymorphic_backfill

slug	entities-blarcamesine
kg_node_id	None
entity_type	entity
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-7637d4197efb
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'entities-blarcamesine'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

41

Outgoing

52

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Blarcamesine

Blarcamesine

Overview

Blarcamesine

Overview

Mechanism of Action

Sigma-1 Receptor Agonism

Muscarinic Receptor Modulation

Combined Multi-Target Effects

Preclinical Data

Amyloid and Tau Models

Neuroprotection Mechanisms

Combination Therapy Potential

Clinical Development

Phase 1 Studies

First-in-Human Study (NCT02727681)

Phase 2 Studies

Study 2a (NCT03071389)

Study 2b (NCT03474727)

Phase 3 Program (ARIA-AD)

ARIA-AD Study (NCT04343469)

Parkinson's Disease Program

Phase 2 Study (NCT04448938)

S1R in Parkinson's Disease Pathology

Pharmacokinetics and Pharmacodynamics

Pharmacokinetic Parameters

CNS Penetration

Pharmacodynamic Markers

Drug Interactions

Special Populations

Safety and Tolerability

Adverse Events in Phase 2b

Key Safety Findings

Long-term Safety

Competitive Landscape

Comparison to Approved AD Therapies

Advantages of Blarcamesine

Other S1R-Targeting Drugs in Development

Biomarkers and Patient Selection

Diagnostic Biomarkers for Patient Selection

Treatment Response Biomarkers

Patient Enrichment Strategies

Intellectual Property

Patent Portfolio

Regulatory Exclusivity

Market Analysis

Target Patient Population

Commercial Projections

Health Economics

Cost-Effectiveness

Value Proposition

Real-World Evidence and Post-Marketing Surveillance

Planned Observational Studies

Pharmacovigilance Requirements

Combination Therapy Rationale

Synergistic Mechanisms

Combination Trial Designs

Mechanistic Insights from Human Data

Neuroimaging Findings

Biomarker Correlations

Manufacturing and Quality

Production Process

Quality Specifications

Regulatory Strategy

US Pathway

EU Pathway

Global Strategy

Patient Access and Reimbursement

US Market Access

Pricing Strategy

Competitive Positioning Summary

Strengths

Challenges

Opportunities

See Also

Additional References

External Links

References

💬 Discussion